Reviva Pharmaceuticals Holdings, Inc. Common Stock
RVPH Real Time Price USDRecent trades of RVPH by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by RVPH's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Methods for treating pulmonary fibrosis Aug. 06, 2024
-
Patent Title: Methods for treating pulmonary hypertension Oct. 15, 2019
-
Patent Title: Arylpiperazine derivatives and methods of utilizing same May. 22, 2018
-
Patent Title: Methods for treating attention deficit hyperactivity disorder Mar. 06, 2018
-
Patent Title: Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives Jul. 04, 2017
-
Patent Title: Arylpiperazine derivatives and methods of utilizing same Mar. 28, 2017
-
Patent Title: Synthesis, methods of using, and compositions of cycloalkylmethylamines Apr. 05, 2016
-
Patent Title: Cycloalkylmethylamines Mar. 29, 2016
-
Patent Title: Arylpiperazine derivatives and methods of utilizing same Feb. 09, 2016
-
Patent Title: Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives Jan. 19, 2016
-
Patent Title: Methods of using cycloalkylmethylamine derivatives Aug. 04, 2015
-
Patent Title: Arylpiperazine derivatives and methods of utilizing same Mar. 17, 2015
-
Patent Title: Methods of utilizing arylpiperazine derivatives Oct. 14, 2014
-
Patent Title: Synthesis, methods of using, and compositions of cycloalkylmethylamines Mar. 11, 2014
-
Patent Title: Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives Dec. 10, 2013
-
Patent Title: Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors Nov. 12, 2013
-
Patent Title: Compositions, synthesis, and methods of utilizing quinazolinedione derivatives Nov. 05, 2013
-
Patent Title: Methods of utilizing arylpiperazine derivatives Jun. 11, 2013
-
Patent Title: Cycloalkylmethylamines May. 21, 2013
-
Patent Title: Methods of utilizing arylpiperazine derivatives Apr. 30, 2013
-
Patent Title: Methods of using cycloalkylmethylamines Feb. 12, 2013
-
Patent Title: Cycloalkylmethylamines Dec. 25, 2012
-
Patent Title: Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors Aug. 21, 2012
-
Patent Title: Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents Aug. 21, 2012
-
Patent Title: Compositions, synthesis, and methods of using piperazine based antipsychotic agents Jun. 26, 2012
-
Patent Title: Compositions, synthesis, and methods of utilizing arylpiperazine derivatives May. 29, 2012
-
Patent Title: Synthesis, methods of using, and compositions of cycloalkylmethylamines Aug. 02, 2011
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of RVPH in WallStreetBets Daily Discussion
Recent insights relating to RVPH
Recent picks made for RVPH stock on CNBC
ETFs with the largest estimated holdings in RVPH
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view RVPH Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.